Sandow, L., Grenet, J., Kardosh, A., Chen, E. Y., Pegna, G. J., Mayo, S. C., Eil, R., Worth, P. J., Rocha, F. G., Nabavizadeh, N., Grossberg, A., Guimaraes, A., Foster, B., Goodyear, S. M., Taber, E., Keith, D., Mills, G. B., Sears, R. C., Sheppard, B. C., Lopez, C. D. (2025). NeoOPTIMIZE: Phase II trial of adaptive switching of neoadjuvant FOLFIRINOX (FFX) to gemcitabine/nab-paclitaxel (GA) resectable/borderline resectable (BR)/locally advanced (LA) pancreatic adenocarcinoma (PDAC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4190